モンテルカストナトリウム水和物

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H318：重篤な眼の損傷

• 注意書き

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

モンテルカストナトリウム水和物 価格

モンテルカストナトリウム水和物 化学特性,用途語,生産方法

• 外観

  白色～ほとんど白色粉末～結晶

• 用途

  ロイコトリエン受容体阻害作 用を有します。

• 効能

  抗アレルギー薬, 喘息治療薬, ロイコトリエン受容体拮抗薬

• 商品名

  キプレス (杏林製薬); キプレス (杏林製薬); キプレス (杏林製薬); シングレア (MSD); シングレア (MSD); シングレア (MSD)

• 説明

  Montelukast was launched as Singulair in Mexico and Finland for the management of mild to moderate asthma inadequately controlled by inhaled corticosteroids and short-acting beta2-agonists. Montelukast can be obtained by an seven-step synthesis from 3-[2(E)-(7-chloroquinolin-2-yl)vinyl] benzaldehyde. Montelukast is a potent, selective and orally active antagonist of the CysLT1 (formerly called LTD4) receptor, thus blocking the effects of the cysteinyl leukotrienes LTC4, LTD4 and LTE4 on microvascular permeability and the activation of eosinophils. Montelukast represents the third molecule of this class which has been approved in asthma after pranlukast (1995) and zafirlukast (1996). Montelukast has been studied extensively in placebo-controlled clinical trials, in mildly or severe asthmatic patients challenged with LTD4 or exercise. A variety of acute bronchoconstricting challenges were inhibited or attenuated with all doses used. Montelukast demonstrated clinically significant improvements in the parameters of asthma control associated with an appreciable improvement in quality of life., reducing days with asthma exacerbations and allowing significant tapering of corticosteroids. Montelukast is well-tolerated and only needs to be administered once a day.

• 化学的特性

  White or almost white, hygroscopic powder.

• 使用

  Montelukast sodium is a potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity. It is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.

• 主な応用

  Montelukast sodium hydrate has been used as a positive control drug to study the protective effects of Gumiganghwal-tang aqueous extract (GGTA) against airway inflammation and pulmonary fibrosis.

• 定義

  ChEBI: Montelukast sodium is an organic sodium salt. It contains a montelukast(1-). It is a drug used to treat symptoms of asthma, such as trouble breathing, tight chest, wheezing, coughing, and runny nose. Montelukast sodium blocks the action of a substance that causes airways in the lungs to narrow and causes other symptoms of asthma. It is a type of leukotriene receptor antagonist and a type of antiasthmatic agent. Also called Singulair.

• 適応症

  Montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. It was successfully developed by the Merck Company (German) and had entered into market in Canada, Finland, and Mexican in 1997. It is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment.

• 副作用

  Common side effects of montelukast include upper respiratory infection, fever, headache, sore throat, cough, stomach pain, diarrhea, earache or ear infection, flu, runny nose, and sinus infection.
  www.mayoclinic.org

• Mode of action

  Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4).

• 参考文献

  1) Lynchet al.(1999),Characterization of the human cysteinyl leukotriene CysLT1 receptor; Nature,399789 DOI:10.1038/21658
  2) Joneset al. (1995),Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist; Can. J. Physiol. Pharmacol.,73191 DOI:10.1139/Y95-028
  3) Reisset al.(1998),Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group; Arch. Intern. Med.,1581213 DOI:10.1001/ARCHINTE.158.11.1213
  4) Zhaoet al.(2011),Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats; J. Pharm. Pharmacol.,63550 DOI:10.1111/j.2042-7158.2010.01238.x
  5) Lenzet al.(2014),Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction; Neuroscience,277859 DOI:10.1016/j.neuroscience.2014.07.058
  6) Huberet al.(2011)Inhibition of leukotriene receptors boosts neural progenitor proliferation; Cell Physiol. Biochem.,28793 DOI:10.1159/000335793
  

モンテルカストナトリウム水和物 上流と下流の製品情報

モンテルカストナトリウム水和物 生産企業

Global(816)Suppliers

モンテルカストナトリウム水和物 スペクトルデータ(¹HNMR)

151767-02-1, モンテルカストナトリウム水和物 キーワード